Replies to post #19633 on Revive Therapeutics Ltd (RVVTF)

[INTHEKNOW1]

THANK YOU I KEPT DRAWING BLANKS EVERYWHERE! LOL

[mc67]

Revive Therapeutics Ltd. (OTC: RVVTF) announced on November 18th, it has entered into an exclusive research collaboration agreement with PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation and a specialty psychedelics pharmaceutical company, to accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds.

"Revive continues to be focused on developing novel uses for psilocybin that leverages our proprietary oral thin film delivery technology as a differentiated therapeutic approach," said Michael Frank, CEO of Revive.

"We are excited to advance the development of PharmaTher's recent discovery in the potential of psilocybin to treat certain cancers such as Liver Carcinoma, Melanoma, Breast Neoplasms, Kidney Neoplasms and Acute Myeloid Leukemia.

We are also leveraging PharmaTher's panaceAI™ discovery AI platform to discover new uses of undisclosed psychedelic compounds to be potentially used with our oral thin film delivery technology and expand our psychedelics drug pipeline."

[Ecomike]

If they pull that off, it will be huge, huge demand for decades, but short term the Bucillamine #Covid19 trial is what will take it to $10 or $20/share, depending on the results in 2 weeks and early next year.

https://www.prnewswire.com/news-releases/push-for-alternative-therapies-prods-researchers-towards-psilocybin-301192743.html